Pemetrexed Approval for Frontline Pembrolizumab/Chemo Combo in NSCLC Gets ExpansionApril 10th 2019
The FDA expanded the indication for for pemetrexed (Alimta) injection plus pembrolizumab (Keytruda) and platinum-based chemotherapy for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) without EGFR or ALK alterations.
FDA Advises Against Starting Olaratumab for Soft Tissue SarcomaApril 9th 2019
The FDA recommends that no new patients with advanced soft tissue sarcoma (STS) be treated with olaratumab (Lartruvo) plus doxorubicin, following the negative results of the phase III ANNOUNCE trial.
Nurses Must Adapt to Meet the Needs of a Diverse Patient PopulationApril 7th 2019
Rapid changes occurring nationally and worldwide—including shifts in demographics, languages, epidemiological patterns, and social systems— have direct implications for patient care. These trends are projected to continue, and nurses need to be prepared to care for increasingly diverse patient populations.